- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03461042
The Study of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of Benzodiazepine (BZD) and Non-BZD Hypnotics on Chronic Insomnia (BRED)
The Placebo Controlled Randomized Double Blind Multicenter Study to Investigate Effectiveness and Safety of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of BZD and Non-BZD Hypnotics on Chronic Insomnia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Tokyo
-
Shibuya-ku, Tokyo, Japan, 151-0053
- Yoyogi Sleep Disorder Clinic, Foundation of Sleep and Health Science
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects meeting Criteria 1 or 2 and Criteria 3 and all subsequent criteria will be included in the study:
- Patients diagnosed as chronic insomnia having sleep onset disturbance, and with a duration of the disease of at least 6 months
- Patients diagnosed with chronic insomnia comorbid with mood disorders (depression or bipolar disorder) can be included to this study if they have remission of mood symptoms.
Patients taking (non-)BZD hypnotics (including etizolam at bedtime) at a fixed dose in the following patterns since at least 1 month prior to consent (over 90% of drug compliance should be confirmed at the time of medical interview):
- Patients taking 2 drugs at the usual dose (1 unit)
- Patients taking 3 drugs at the usual dose (1 unit)
- Patients taking 4 drugs at the usual dose (1 unit)
- Patients taking a drug at 2-fold of the usual dose (2 units)
- Patients taking a drug at 2-fold of the usual dose (2 units) and a drug at the usual dose (1 unit)
- Patients taking a drug at 2-fold of the usual dose (2 units) and 2 drugs at the usual dose (1 unit)
Patients taking 2 drugs at 2-fold of the usual dose (2 units) Patients whose total dosage are 2~4 units of 1~4 drugs can be also included. But attention needed not to conflict with exclusion criteria 2.
※Dosage cannot exceeded 2 units per 1 drug.
- Patients whose symptoms of insomnia were stabilized, and the investigators determined that the (non-) BZD hypnotics could be reduced or discontinued
- Patients aged 20 years or older at the time of consent
- Patients who are willing to comply with algorithm for dose reduction and discontinuation
- Patients who can understand the content of the study and provide consent to participate in the study in writing on their own will.
Exclusion Criteria:
Subjects meeting any of the following criteria will not be included in the study:
- Patients with secondary insomnia
- Patients taking (non-)BZD hypnotics at a dose exceeding 2-fold of the usual dose
- Patients taking barbiturate and non-barbiturate hypnotics and Suvorexant.
- Patients taking hypnotics other than medicinal pharmaceuticals (including Over The Counter (OTC), supplements believed to be effective for insomnia and melatonin )
- Patients taking mianserin hydrochloride, mirtazapine, and trazodone hydrochloride
- Patients taking antipsychotics
Patients taking anxiolytic or clonazepam at bedtime
*Patient taking anxiolytic and/or clonazepam at times except for bed-time will be included in the study. However, dosage and timing of administration can not be changed during the study period.
- Patients who took ramelteon within 1 month prior to the informed consent
- Patients in whom the dose of psychotropics except for the items 2~7 were changed within 1 month prior to the informed consent
- Patients who are comorbid with depression or bipolar disordered and in whom depressive symptoms have not remitted
- Patients in whom frequency in Q9 of PHQ "thoughts that you would be better off dead or thoughts of hurting yourself in some way" is "more than half the days (in the past 2 weeks)" or the total score is 10 or higher
- Patients with dementia, schizophrenia, drug dependence and alcoholic
- Patients with liver/kidney disorder, female subjects who are pregnant or in breast-feeding, and malignant neoplasm
- Night workers
- Patients meeting contraindications for ramelteon
- Other patients judged ineligible for participation in the study by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm R
Co-administer following medication for 12 weeks since informed consent; R group: taking capsule of Ramelteon 8mg once daily before sleeping.
|
Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent
|
Placebo Comparator: Arm PL
Co-administer following medication for 12 weeks since informed consent; Placebo group: taking capsule of Placebo once daily before bedtime.
|
Placebo capsule once daily before bedtime for 12 weeks since informed consent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The achievement ratio of the 50% dose reduction of (non-)BZD hypnotics (Diazepam conversion value) at 12weeks or withdrawal without any deterioration of insomnia symptoms.
Time Frame: 12 weeks
|
Evaluate the achievement ratio of the 50% or more of dose reduction by Participant's diary
|
12 weeks
|
The rate of subjects who achieved more than 50% dose reduction of (non-)BZD hypnotics (Diazepam conversion value) at 12 weeks or withdrawal since informed consent.
Time Frame: 12 weeks
|
The rate of subjects who achieved more than 50% of dose reduction (Diazepam conversion value) will be assessed by Participant's diary
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The achievement ratio of the 50% dose reduction (Diazepam conversion value) at 4weeks and 8weeks
Time Frame: at 4 weeks and 8weeks
|
The rate of subjects who achieved more than 50% dose reduction (Diazepam conversion value) will be assessed by Participant's diary
|
at 4 weeks and 8weeks
|
The average of the dose reduction rate at 4weeks, 8weeks and 12weeks
Time Frame: at 4 weeks, 8weeks and 12 weeks
|
The average of the dose reduction rate will be assessed by Participant's diary
|
at 4 weeks, 8weeks and 12 weeks
|
The achievement ratio of the 100% dose reduction at 12weeks or withdrawal
Time Frame: 12 weeks
|
The achievement ratio of the 100% dose reduction will be assessed by Participant's diary
|
12 weeks
|
The variation in total score of Pittsburg Sleep Quality Index (PSQI) at 4weeks, 8weeks and 12weeks
Time Frame: at 0, 4, 8 and 12 weeks
|
The variation in total score of PSQI will be assessed by the PSQI value sets sets at week 0, 4, 8 and 12. (The range of total score is 0-21.
Higher scores represent worse tendency of the symptoms.)
|
at 0, 4, 8 and 12 weeks
|
The variation in total score of Athens Insomnia Scale (AIS) at 4weeks, 8weeks and 12weeks
Time Frame: at 0, 4, 8 and 12 weeks
|
The variation in total score of AIS will be assessed by the AIS value sets at week 0, 4, 8 and 12. (The range of total score is 0-24.
Higher scores represent worse tendency of the symptoms.)
|
at 0, 4, 8 and 12 weeks
|
The variation in Patient health questionnaire (PHQ-9) score at 4weeks, 8weeks and 12weeks
Time Frame: at 0, 4, 8 and 12 weeks
|
The variation in PHQ-9 score will be assessed by the PHQ-9 value sets at week 0, 4, 8 and 12. (The range of total score is 0-27.
Higher scores represent worse tendency of the symptoms.)
|
at 0, 4, 8 and 12 weeks
|
Guide to the use of the clinical withdrawal assessment scale for benzodiazepines (CIWA-B) score at 4weeks, 8weeks and 12weeks
Time Frame: at 4, 8 and 12 weeks
|
The variation in CIWA-B (Guide to the use of the clinical withdrawal assessment scale for benzodiazepines) score will be assessed by the CIWA-B value sets at week 4, 8 and 12. (The range of total score is 0-80.
Higher scores represent worse tendency of the symptoms.)
|
at 4, 8 and 12 weeks
|
Patient global impression of therapy (PGI) score at 12weeks or withdrawal
Time Frame: 12 weeks
|
PGI(Patient global impression of therapy) score will be assessed by the PGI value sets at 12weeks or withdrawal.
(The range of total score is 0-21.
Higher scores represent worse tendency of the symptoms.)
|
12 weeks
|
The variation in Ben-dep(Benzodiazepine Dependence Self-Report Questionnaire) score at 12weeks or withdrawal
Time Frame: at 0 and 12 weeks
|
The variation in Ben-dep score will be assessed by the Ben-dep value sets at 0 and 12weeks or withdrawal.
(The range of total score is 0-100.
Higher scores represent worse tendency of the symptoms.)
|
at 0 and 12 weeks
|
Adverse Events
Time Frame: 12 weeks
|
Adverse Events will be determined by the latest version of MedDRA/J (Medical Dictionary for Regulatory Activities/J).
|
12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yuichi Inoue, MD, Ph.D., Yoyoghi Sleep Disorder Clinic / Foundation of Sleep and Health Science
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 293/CR1-003 / TRIPSYCHI1407
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Insomnia
-
University of AarhusTrygFonden, Denmark; Enversion A/SActive, not recruiting
-
Posit Science CorporationCompletedInsomnia ChronicUnited States
-
Jun SongUnknown
-
University of ManitobaCompleted
-
University of Missouri-ColumbiaUniversity of FloridaCompleted
-
University of AarhusTrygFonden, Denmark; Enversion A/SCompleted
-
University of TromsoUniversity Hospital of North Norway; Diakonhjemmet HospitalNot yet recruitingPain, Chronic | Insomnia Chronic | Insomnia Due to Medical ConditionNorway
-
University of Missouri-ColumbiaCompletedPain, Chronic | Insomnia ChronicUnited States
-
Diakonhjemmet HospitalActive, not recruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Chronic Disease | Sleep Disturbance | Insomnia Chronic | Insomnia Due to Medical Condition | Insomnia, PsychophysiologicalNorway
Clinical Trials on Ramelteon 8mg
-
Centennial Medical CenterRecruiting
-
Associação Fundo de Incentivo à PesquisaUnknownCovid19 | Lung Injury
-
Virginia Commonwealth UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
TakedaCompletedChronic Obstructive Pulmonary Disease | COPDUnited States
-
TakedaCompletedSleep Apnea, ObstructiveUnited States
-
Southern Arizona VA Health Care SystemUnknownGastroesophageal Reflux Disease | Chronic InsomniaUnited States
-
University of California, San DiegoActive, not recruitingDelirium | Sleep Deprivation
-
TakedaCompleted
-
Massachusetts General HospitalWithdrawnParkinson's Disease | Sleep Disorders | Dementia With Lewy Bodies | Huntington's Disease | Circadian DysregulationUnited States
-
Charlottesville NeuroscienceTakeda Pharmaceuticals North America, Inc.TerminatedMigraine HeadacheUnited States